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Immunohistochemical analysis of nm23 gene product/NDP kinase
expression in pulmonary adenocarcinoma: lack of prognostic value
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Summary Levels of nm23 gene product/nucleoside diphosphate kinase (NDP kinase) expression have been
demonstrated to correlate inversely with metastatic potential in several tumours, indicating that this could be a
useful tool as a prognostic indicator. Using an antibody to NDP kinase, levels of nm23 gene product/NDP
kinase expression in pulmonary adenocarcinoma were examined immunohistochemically. Of 88 patients tested,
39 (44%; Group B) showed strong immunoreactivity for NDP kinase in most of cancer cells within the
tumour tissues, while 49 (56%; Group A) contained few or no NDP kinase-positive cancer cells. Nm23 gene
product/NDP kinase was expressed independently of clinicopathological factors, and unexpectedly, no correla-
tion of survival rates between both Groups could be demonstrated. Thus, in pulmonary adenocarcinoma,
levels of nm23 gene product/NDP kinase expression may lack prognostic value.
Accurate prediction of the malignant potential of lung
cancer, reflecting biological features, such as progression,
invasiveness, and metastasis, is an important goal in clinical
oncology. In lung cancer, however, and adenocarcinoma in
particular, there are no reliable prognostic markers reported
for immunohistochemical use, although several candidates
have been recently, including oncogene products (Harada et
al., 1992), growth factors (Tateishi et al., 1991), proteinases
(Ishida et al., 1991), antiproteinases (Higashiyama et al.,
1992), and blood type expression (Lee et al., 1991).
It has recently been recognised that the nm23 gene and its
product are closely related to the metastatic potential of
some tumour cells (Steeg et al., 1988; Liotta et al., 1991).
Low levels of nm23 mRNA and the corresponding protein
have been reported to reflect high metastatic potential in
both experimental animal tumours and human breast cancer
(Steeg et al., 1988; Bevilacqua et al., 1989; Rosengard et al.,
1989; Barnes et al., 1991; Liotta et al., 1991; Hennesy et al.,
1991). The expression of nucleoside diphosphate kinase
(NDP kinase), which is now known to be identical to the
nm23 gene product (Kimura & Shimada, 1988; Rosengard et
al., 1989; Kimura et al., 1990; Wallet et al., 1990), has been
investigated in breast cancer by immunohistochemistry: the
results suggest that the nm23 gene product/NDP kinase ex-
pression may possibly be a useful prognostic marker
(Hirayama et al., 1991). Leone et al. (1991) first reported
somatic allelic deletion of the nm23 gene in pulmonary
adenocarcinoma, but to our knowledge, studies of the pro-
duct level of the nm23 gene have not yet been carried out in
lung cancer. We therefore performed immunohistochemical
analysis of nm23 product/NDP kinase expression in pul-
monary adenocarcinoma to determine its prognostic value.
Materials and methods
Formalin-fixed and paraffin-embedded tissue blocks from 88
surgically resected specimens of pulmonary adenocarcinoma
in our institute, which were well-preserved for immunohisto-
chemical study were examined. All patients except those in
stage IV (two patients) due to pulmonary metastasis under-
went operations, which seemed curative at the time of oper-
ation. Of the 88 patients, 55 were men and 33 were women;
their ages ranged from 19 to 78 (mean 61.6). According to
the international TNM staging system (Mountain, 1986), 42 of
the patients were in pathological stage I (p-stage I), 11 were
in pathological stage II (p-stage II), 31 were in pathological
stage IIIA (p-stage IIIA), two were in pathological stage IIIB
(p-stage IV). With regard to histological degree of differ-
entiation, 29 cases were well differentiated, 38 were
moderately differentiated, and 21 were poorly differentiated.
Immunohistochemistry was performed according to a
modification of the method of Hsu et al. (1981). Briefly,
sections (4 jm thick) from each tissue block were
deparaffinised, and endogenous peroxidase activity was
blocked using 0.3% hydrogen peroxide in methanol. After
treatment in 2% normal goat serum, they were incubated
with specific antibody to NDP kinase (diluted 1:300), raised
against the NDP kinase from rat liver (Kimura & Shimada,
1988). The specificity of the antibody had been confirmed
previously by immunoelectrophoretic blotting (Kimura &
Shimada, 1988), and this antibody is known to be suitable
for immunohistochemical applications (Hirayama et al.,
1991). Sections were treated with biotinylated goat anti-
rabbit IgG (Vector), and subsequently with avidin-biotin
peroxidase complex (Vectastatin ABC kit, Vector).
The peroxidase reaction used 0.02%, 3,3'-diaminobenzidine
tetrahydrochloride in 0.05 M TRIS buffer, pH 7.6, containing
0.01% hydrogen peroxide. Sections were counterstained with
Mayer's hematoxylin.
Immunostaining results were assessed semi-quantitatively
by two of the authors, taking into account the percentage of
NDP kinase-positive cancer cells within maximum cut-
surface specimens of the tumour tissues, including the sur-
rounding non-cancerous lung tissues. The patients were
classified into two groups: Group A patients had less than
30% NDP kinase-positive cancer cells, whilst those in Group
B had more than 30%. The chi-quare test was sued for
statistical analysis. The Kaplan-Meier method was used to
calculate postoperative survival rate, and prognostic
significance was evaluated by the generalised Wilcoxon test.
Results
In this immunohistochemical study using formalin-fixed and
paraffin embedded samples, NDP kinase expression was
observed in the cytoplasm of pulmonary adenocarcinoma
cells with patchy, or often, diffuse staining pattern. Non-
cancerous parts of the lung contained no or little NDP
kinase with some exceptions: bronchial serous glands, their
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ducts, and some bronchial epithelial often showed immuno-
reactivity for NDP kinase (Figure 1).
Thirty-nine (44%) of 88 pulmonary adenocarcinoma
patients belonged to Group B, and 49 (56%) to Group A.
Table I shows the relationship between NDP kinase
immunoreactivity and clinicopathological status. NDP kinase
was expressed independently of p-stage, tumour size, nodal
involvement or histological differentiation. The trend towards
greater tumour progression, smaller size, positive nodal
involvement and histologically poor differentiation in Group
B was not statistically significant.
Postoperative survival curves for the two groups, including
patients in stages I, II, IIIA and IIIB, undergoing a curative
operation, are shown in Figure 2a. The average 5-year survival
rates were 63% in Group A and 42% in Group B (P = 0.15).
Figure 2b shows that the average 5-year survival rates for
stage I patients were 76% in Group A and 58% in Group B
(P = 0.35). There was no significant difference in survival
rates between the Groups.
Discussion
In the present study, in which we used an immunohisto-
chemical technique with an antibody against rat NDP kinase,
we demonstrated that there was no relationship between the
extent of nm23 gene product/NDP kinase expression and the
grade of malignancy in pulmonary adenocarcinoma. In parti-
cular, indicators of metastatic potential such as nodal
involvement status appeared to be independent of this ex-
pression. Our results disagree with those of several previous
breast cancer studies as well as studies of experimental
tumours (Bevilacqua et al., 1989; Rosengard et al., 1989;
Wallet et al., 1990; Barnes et al., 1991; Hennesy et al., 1991;
Hirayama et al., 1991; Liotta et al., 1991). Patients with high
levels of NDP kinase expression unexpectedly included many
rather advanced cases.
Similar results have been recorded in several other human
malignancies. Aggressive neuroblastoma showed higher levels
of nm23 gene protein with N-myc gene amplification (Hailat
et al., 1991). In colonic cancer, in contrast to the evidence of
nm23 allelic gene deletions in aggressive cases (Cohen et al.,
1991), nm23 mRNA levels increased in both localised and
metastatic disease (Haut et al., 1991). In addition, Lacombe
et al. (1991) recently showed that some human solid tumours,
including breast cancer, overexpressed NDP kinase, irrespec-
tive of lymph node involvement. Our present data confirm
that nm23 gene product/NDP kinase expression is not always
associated with indicators of tumour malignancy such as
metastatic potential or prognosis.
Currently, these discrepancies, regarding the significance of
the nm23 gene product/NDP kinase expression in human
malignancy, are not understood, but two explanations are
suggested. First, the biological significance of NDP kinase
expression may be quite different in different tissues. High
levels of expression are associated with better prognosis in
breast carcinoma (Hirayama et al., 1991), and are also found
in normal breast epithelium (Barnes et al., 1991). In contrast,
expression is in general lower in normal colonic epithelium
than in carcinoma (Haut et al., 1991), and we have also
demonstrated the same situation in the lung by immunohisto-
chemistry using the same antibody as Hirayama et al. (data
not shown). Secondly, the nm23 gene product/NP kinase is
now demonstrated to consist of two isotypes, nm23-H1 and
nm23-H2 (Stahl et al., 1991), which are identical with chain
A and chain B of NDP kinase, respectively (Gilles et al.,
1991). The expression of the nm23-HI isotype is reduced in
breast cancer with higher metastatic potential (Hennesy et
al., 1991; Leone et al., 1991; Stahl et al., 1991). Allelic loss of
the nm23-HI gene on chromosome 17 is observed in pul-
monary adenocarcinoma (Leone et al., 1991), but it is still
unknown which type of predominant with regard to the
metastatic potential of lung cancer. The antibody used in the




Figure 1 Nm23 gene product/NDP kinase expression in pul-
monary adenocarcinoma shown by immunostaining using anti-
NDP kinase antibody. a Tissue from a Group A patient shows
immunoreactivity for NDP kinase in a few cancer cells (arrow)
(original magnification, x 33). b, In tissue from a Group B
patient, NDP kinase is strongly expressed in almost all the cancer
cells (original magnification, x 33). c, In tissue from another
Group B patient, most of cancer cells contain NDP kinase
(arrow), while only a small number of bronchial epithelia show
immunoreactivity for NDP kinase in the normal lung tissues
(arrowhead) (original magnification, x 25).
In conclusion, this immunohistochemical analysis shows
that the nm23 gene product/NDP kinase in pulmonary
adenocarcinoma is expressed independently of clinico-
pathological parameters. There is no correlation between
expression level and patient survival. Thus, nm23 gene
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Table I nm23 gene product/NDP kinase expression in pulmonary
adenocarcarima
No. of Group A' Group Ba
patients (%) (%)
p-Stage
I 42 27 (64) 15 (36)
II 11 5 (45) 6 (55)
IIIA 31 16 (52) 15 (48)
IIIB 2 0 (0) 2 (100)
IV 2 1 (50) 1 (50)
Tumour size (mm)
<30 38 18 (47) 20 (53)
>31 50 23 (62) 19 (38)
Nodal involvement
Negative 47 29 (62) 18 (38)
Positive 41 20 (49) 21 (51)
Differentiation
Well 29 17 (59) 12 (41)
Moderate 38 21 (55) 17 (45)
Poor 21 11 (52) 10 (48)
Total 88 49 (56) 39 (44)
aSee text.
product/NDP kinase expression is unlikely to be useful as a
prognostic indicator, in contrast to previous results in breast
cancer. Further attempts with specific probes to each isotype,
nm23-HI and nm23-H2, respectively, on the product as well
as on the gene level are needed to elucidate the clinical and
biological significance of the nm23 gene product/NDP kinase
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Figure 2 a Survival curves of cases with curative operation
(P=O0.15). b Survival curves of stage I cases (P=0.35).
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